FCRL6

Across TCGA pan-cancer cohorts, FCRL6 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated FCRL6 data layer compared with 27 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FCRL6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated FCRL6 expression acts as an unfavorable survival marker.

LUAD, UCEC, and BLCA are the cancer types where FCRL6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	All	0.079	0.791	<.001	36	view →
UCEC	OS	Median	IV	0.066	0.755	<.001	12	view →
BLCA	OS	Median	III,IV	0.188	0.582	.009	12	view →
PCPG	DFS	Median	All	0.104	0.904	<.001	6	view →
LUSC	DFS	Median	All	0.165	0.707	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

FCRL6–LUAD (OS)

Open the LUAD breakdown →